Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
![Decorative image.](/media/tnwj5bxg/riad-large-banner.jpg?width=1792&height=900&v=133517223228800000&format=webp)
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma – A legacy of quality for a better future Insight, Corporate 24 June 2024 Hikma – A legacy of quality for a better future
- Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D Press Release, Corporate 17 June 2024 Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D
- Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting Press Release, Corporate 06 June 2024 Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House meeting
- Hikma opens new UK office to support NHS supply, strengthening European presence Press Release, Corporate 03 June 2024 Hikma opens new UK office to support NHS supply, strengthening European presence